WELCURE DRUGS & PHARMACEUTICALS LTD.

NSE : NABSE : 524661ISIN CODE : INE331C01017Industry : TradingHouse : Private
BSE4.870.07 (+1.46 %)
PREV CLOSE ( ) 4.80
OPEN PRICE ( ) 4.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 45156
TODAY'S LOW / HIGH ( )4.85 4.87
52 WK LOW / HIGH ( ) 3.25.48
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2010Mar2009Mar2008Mar2007Mar2006
Profit Before Tax-17.75-58.52-18.93-7.80-17.69
Adjustment15.5741.8817.879.617.04
Changes In working Capital12.6618.4214.803.20-5.36
Cash Flow after changes in Working Capital10.481.7913.745.00-16.01
Cash Flow from Operating Activities9.661.4212.953.93-16.62
Cash Flow from Investing Activities1.929.950.77-1.43-12.18
Cash Flow from Financing Activities-12.25-9.85-14.29-2.8129.64
Net Cash Inflow / Outflow-0.681.51-0.57-0.310.84
Opening Cash & Cash Equivalents2.531.011.581.891.05
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange FluctuationsNANANANANA
Closing Cash & Cash Equivalent1.842.531.011.581.89

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.